![John Choi](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
John Choi is currently the Vice President of Regulatory Affairs at TFF Pharmaceuticals, Inc. He previously held the same position at Stellular Bio, Inc., Ambys Medicines, Inc., and Abata Therapeutics, Inc. Mr. Choi received his undergraduate and graduate degrees from The Johns Hopkins University.
| Empresas | Cargo | Inicio |
|---|---|---|
| TFF PHARMACEUTICALS, INC. | Consejero General | - |
| Empresas | Cargo | Fin |
|---|---|---|
Ambys Medicines, Inc.
 Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Develops regenerative medicine therapies for serious liver diseases | Consejero General | - |
Stellular Bio, Inc.
 Stellular Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Develops technology to produce independent human platelets from human induced pluripotent stem cells | Consejero General | - |
Abata Therapeutics, Inc.
 Abata Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treg cell therapies for serious autoimmune and inflammatory diseases | Consejero General | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
| Empresas privadas | 5 |
|---|---|
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stellular Bio, Inc.
Stellular Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Develops technology to produce independent human platelets from human induced pluripotent stem cells | Commercial Services |
TFF Pharmaceuticals, Inc.
 TFF Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures inhaled dry powder drugs for the treatment of pulmonary diseases and conditions | Health Technology |
Ambys Medicines, Inc.
Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Develops regenerative medicine therapies for serious liver diseases | Health Technology |
Abata Therapeutics, Inc.
Abata Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treg cell therapies for serious autoimmune and inflammatory diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
